Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines

Talebi, Somayeh; Bolhassani, Azam; Sadat, Seyed Mehdi; Vahabpour, Rouhollah; Agi, Elnaz; Shahbazi, Sepideh

doi:10.1016/j.biopha.2016.11.115

Cited by 13 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…91 This is a potent immune adjuvant for inducing cellular and humoral immune responses and has been used in vaccines against viral infections such as HIV and HPV. [90][91][92][93] HBD-3 is the third adjuvant in our vaccine, used as adjuvant to viruses such as influenza and MERS-CoV. 28,94 This peptide blocks viral fusion using creating a protective barricade of immobilized surface proteins.…”

Section: Discussionmentioning

confidence: 99%

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Yazdani¹,

Rafiei²,

Yazdani³

et al. 2020

IDR

View full text Add to dashboard Cite

Background: To date, no specific vaccine or drug has been proven to be effective against SARS-CoV-2 infection. Therefore, we implemented an immunoinformatic approach to design an efficient multi-epitopes vaccine against SARS-CoV-2. Results: The designed-vaccine construct consists of several immunodominant epitopes from structural proteins of spike, nucleocapsid, membrane, and envelope. These peptides promote cellular and humoral immunity and interferon-gamma responses. Also, these epitopes have a high antigenic capacity and are not likely to cause allergies. To enhance the vaccine immunogenicity, we used three potent adjuvants: Flagellin of Salmonella enterica subsp. enterica serovar Dublin, a driven peptide from high mobility group box 1 as HP-91, and human beta-defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. The tertiary structure of the vaccine protein was predicted and refined by Phyre2 and Galaxi refine and validated using RAMPAGE and ERRAT. Results of ElliPro showed 246 sresidues from vaccine might be conformational B-cell epitopes. Docking of the vaccine with toll-like receptors (TLR) 3, 5, 8, and angiotensinconverting enzyme 2 approved an appropriate interaction between the vaccine and receptors. Prediction of mRNA secondary structure and in silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli. Conclusion: Our results demonstrated that the multi-epitope vaccine might be potentially antigenic and induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, it has a high-quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli .

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Yazdani¹,

Rafiei²,

Yazdani³

et al. 2020

IDR

View full text Add to dashboard Cite

show abstract

“…The HIV-1 Nef gene was cloned into the NheI/BamHI sites of the pcDNA 3.1 eukaryotic vector. The gp96 and HMGB1 genes were previously cloned into the BamHI/KpnI and NotI/EcoRI sites of the pcDNA3.1 (-) vector (Invitrogen) (39,40). Herein, a large-scale purifi cation of plasmid DNA samples (pcDNA3.1, pcDNA-HMGB1, pcDNA-Nef and pcDNA-Gp96) was performed using ion-exchange chromatography with an Endofree plasmid Giga kit (QIAGEN) according to the manufacturer's instructions for mice immunization.…”

Section: Methodsmentioning

confidence: 99%

Improving the potency of DNA vaccine encoding HIV-1 Nef antigen using two endogenous adjuvants in mouse model

Jafarzade¹,

Sadat²,

Yaghobi³

et al. 2017

BLL

View full text Add to dashboard Cite

show abstract

“…The prominent role of HMGB1 in this context was illustrated in murine anti-tumor vaccination models, where HMGB1 blockade abrogated therapeutic effects both in vivo and in vitro (83,84). Because of its ability to activate DCs, synthetic HMGB1 peptides have been investigated as adjuvants to enhance the immunogenicity of vaccines, both against infectious agents and tumors (85)(86)(87). Concerns about the intratumoral application of HMGB1 in malignant tumors are based on the observation that reactive oxygen species, which are often elevated in the TME, can oxidize HMGB1 and neutralize its immunostimulatory activity (88).…”

Section: Hmgb1 and Hmgn1mentioning

confidence: 99%

In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Hepatocellular Carcinoma (HCC) is a highly prevalent malignancy that develops in patients with chronic liver diseases and dysregulated systemic and hepatic immunity. The tumor microenvironment (TME) contains tumor-associated macrophages (TAM), cancer-associated fibroblasts (CAF), regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC) and is central to mediating immune evasion and resistance to therapy. The interplay between these cells types often leads to insufficient antigen presentation, preventing effective anti-tumor immune responses. In situ vaccines harness the tumor as the source of antigens and implement sequential immunomodulation to generate systemic and lasting antitumor immunity. Thus, in situ vaccines hold the promise to induce a switch from an immunosuppressive environment where HCC cells evade antigen presentation and suppress T cell responses towards an immunostimulatory environment enriched for activated cytotoxic cells. Pivotal steps of in situ vaccination include the induction of immunogenic cell death of tumor cells, a recruitment of antigen-presenting cells with a focus on dendritic cells, their loading and maturation and a subsequent cross-priming of CD8+ T cells to ensure cytotoxic activity against tumor cells. Several in situ vaccine approaches have been suggested, with vaccine regimens including oncolytic viruses, Flt3L, GM-CSF and TLR agonists. Moreover, combinations with checkpoint inhibitors have been suggested in HCC and other tumor entities. This review will give an overview of various in situ vaccine strategies for HCC, highlighting the potentials and pitfalls of in situ vaccines to treat liver cancer.

show abstract

Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines

Cited by 13 publications

References 28 publications

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Improving the potency of DNA vaccine encoding HIV-1 Nef antigen using two endogenous adjuvants in mouse model

In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma

Contact Info

Product

Resources

About